Single- and Multiple-Dose Pharmacokinetic, Safety, and Tolerability Profiles of Olanzapine Long-Acting Injection: An Open-Label, Multicenter, Nonrandomized Study in Patients With Schizophrenia

Clinical Therapeutics

Volumn 35, Issue 12, 2013, Pages 1890-1908

  Mitchell, Malcolm ^a   Kothare, Prajakti ^a   Bergstrom, Richard ^b   Zhao, Fangyi ^a   Jen, Kai Yu ^c   Walker, Daniel ^a   Johnson, Jason ^a   McDonnell, David ^a  

^a ELI LILLY AND COMPANY   (United States)

^b INDIANA UNIVERSITY SCHOOL OF MEDICINE   (United States)

^c PharmaNet/i3   (United States)

Author keywords

Long acting injection; Olanzapine; Pharmacokinetics; Safety; Schizophrenia; Tolerability

Indexed keywords

GLUCOSE; OLANZAPINE;

ADULT; AGED; AGITATION; ALCOHOLISM; ANXIETY; ARTICLE; AUDITORY HALLUCINATION; BRIEF PSYCHIATRIC RATING SCALE; DEPRESSION; DISORIENTATION; DIZZINESS; DRUG BLOOD LEVEL; DRUG DOSE COMPARISON; DRUG FATALITY; DRUG MEGADOSE; DRUG RELEASE; DRUG SAFETY; DRUG TOLERABILITY; DRUG WITHDRAWAL; DYSMENORRHEA; FEMALE; GLUCOSE BLOOD LEVEL; HALLUCINATION; HEADACHE; HUMAN; INJECTION SITE ERYTHEMA; INJECTION SITE HEMATOMA; INJECTION SITE INDURATION; INJECTION SITE NODULE; INJECTION SITE PAIN; INJECTION SITE REACTION; INSOMNIA; INTENTION TO TREAT ANALYSIS; LOADING DRUG DOSE; MAJOR CLINICAL STUDY; MALE; MOOD CHANGE; MULTICENTER STUDY; PARANOIA; PSYCHOSIS; RHINOPHARYNGITIS; SCHIZOPHRENIA; SEDATION; SIDE EFFECT; SINGLE DRUG DOSE; SOMNOLENCE; STEADY STATE; SUICIDE ATTEMPT; TENSION; THINKING; TREATMENT DURATION; VOMITING; WEAKNESS; WEIGHT GAIN;

LONG-ACTING INJECTION; OLANZAPINE; PHARMACOKINETICS; SAFETY; SCHIZOPHRENIA; TOLERABILITY;

ADOLESCENT; ADULT; AGED; ANTIPSYCHOTIC AGENTS; BENZODIAZEPINES; DELAYED-ACTION PREPARATIONS; DOSE-RESPONSE RELATIONSHIP, DRUG; DRUG ADMINISTRATION SCHEDULE; FEMALE; HUMANS; INJECTIONS, INTRAMUSCULAR; MALE; MIDDLE AGED; SCHIZOPHRENIA; YOUNG ADULT;

EID: 84890310940     PISSN: 01492918     EISSN: 1879114X     Source Type: Journal    
DOI: 10.1016/j.clinthera.2013.09.023     Document Type: Article

References (26)

1. Davis J.M., Chen N. The effects of olanzapine on the 5 dimensions of schizophrenia derived by factor analysis: combined results of the North American and international trials. J Clin Psychiatry 2001, 62:757-771.
2. Kinon B.J., Liu-Seifert H., Adams D.H., Citrome L. Differential rates of treatment discontinuation in clinical trials as a measure of treatment effectiveness for olanzapine and comparator atypical antipsychotics for schizophrenia. J Clin Psychopharmacol 2006, 26:632-637.
3. Silva de Lima M., de Jesus Mari J., Breier A., Maria Costa A., Pondé de Sena E., Hotopf M. Quality of life in schizophrenia: a multicenter, randomized, naturalistic, controlled trial comparing olanzapine to first-generation antipsychotics. J Clin Psychiatry 2005, 66:831-838.
4. Gilmer T.P., Dolder C.R., Lacro J.P., et al. Adherence to treatment with antipsychotic medication and health care costs among Medicaid beneficiaries with schizophrenia. Am J Psychiatry 2004, 161:692-699.
5. Lacro J.P., Dunn L.B., Dolder C.R., Leckband S.G., Jeste D.V. Prevalence of and risk factors for medication nonadherence in patients with schizophrenia: a comprehensive review of recent literature. J Clin Psychiatry 2002, 63:892-909.
6. Valenstein M., Copeland L.A., Blow F.C., et al. Pharmacy data identify poorly adherent patients with schizophrenia at increased risk for admission. Med Care 2002, 40:630-639.
7. Al-Zakwani I.S., Barron J.J., Bullano M.F., Arcona S., Drury C.J., Cockerham T.R. Analysis of healthcare utilization patterns and adherence in patients receiving typical and atypical antipsychotic medications. Curr Med Res Opin 2003, 19:619-626.
8. Ascher-Svanum H., Zhu B., Faries D.E., et al. The cost of relapse and the predictors of relapse in the treatment of schizophrenia. BMC Psychiatry 2010, 10:2.
9. Beauclair L., McCormick J., Camacho F., Lam A., Luong D. Impact of risperidone long-acting injectable on hospitalisation and medication use in Canadian patients with schizophrenia. J Med Econ 2007, 10:427-442.
10. Olivares J.M., Rodriguez-Morales A., Diels J., et al. e-STAR Spanish Study Group. Long-term outcomes in patients with schizophrenia treated with risperidone long-acting injection or oral antipsychotics in Spain: results from the electronic Schizophrenia Treatment Adherence Registry (e-STAR). Eur Psychiatry 2009, 24:287-296.
11. Meehan K., Zhang F., David S., et al. A double-blind, randomized comparison of the efficacy and safety of intramuscular injections of olanzapine, lorazepam, or placebo in treating acutely agitated patients diagnosed with bipolar mania. J Clin Psychopharmacol 2001, 21:389-397.
12. Wright P., Birkett M., David S.R., et al. Double-blind, placebo-controlled comparison of intramuscular olanzapine and intramuscular haloperidol in the treatment of acute agitation in schizophrenia. Am J Psychiatry 2001, 158:1149-1151.
13. Eli Lilly and Company. Study F1D-EW-LOBE Clinical Study Summary: a study to assess the safety, tolerability, and pharmacokinetics of single and multiple doses of an intramuscular formulation of depot olanzapine (pamoate salt) in stable schizophrenic subjects. PhRMA Clinical Study Results Database. Accessed August 31, 2012. http://www.lillytrials.com/results/ZyprexaLAI.pdf.
14. Kane J.M., Detke H.C., Naber D., et al. Olanzapine long-acting injection: a 24-week, randomized, double-blind trial of maintenance treatment in patients with schizophrenia. Am J Psychiatry 2010, 167:181-189.
15. Lauriello J., Lambert T., Andersen S., Lin D., Taylor C.C., McDonnell D. An 8-week, double-blind, randomized, placebo-controlled study of olanzapine long-acting injection in acutely ill patients with schizophrenia. J Clin Psychiatry 2008, 69:790-799.
16. Tollefson G.D., Beasley C.M., Tran P.V., et al. Olanzapine versus haloperidol in the treatment of schizophrenia and schizoaffective and schizophreniform disorders: results of an international collaborative trial. Am J Psychiatry 1997, 154:457-465.
17. Overall J.E., Gorham D.R. The brief psychiatric rating scale. Psychological Report 1962, 10:799-812.
18. Guy W. Clinical Global Impressions (CGI). In: ECDEU Assessment Manual for Psychopharmacology. Rockville, Md: US Department of Health and Human Services, Public Health Service, Alcohol Drug Abuse and Mental Health Administration, NIMH Psychopharmacology Research Branch; 1976:218-222.
19. Diagnosis and classification of diabetes mellitus. Diabetes Care 2009, 32(suppl 1):S62-S67. American Diabetes Association.
20. Zyprexa [package insert]. Indianapolis, Ind: Eli Lilly and Company; 2010.
21. Mamo D., Kapur S., Keshavan M., et al. D2 receptor occupancy of olanzapine pamoate depot using positron emission tomography: an open-label study in patients with schizophrenia. Neuropsychopharmacology 2008, 33:298-304.
22. Breier A., Berg P.H., Tharoke J.K., et al. Olanzapine versus ziprasidone: results of a 28-week double-blind study in patients with schizophrenia. Am J Psychiatry 2005, 162:1879-1887.
23. Gureje O., Miles W., Keks N., et al. Olanzapine vs risperidone in the management of schizophrenia: a randomized double-blind trial in Australia and New Zealand. Schizophr Res 2003, 61:303-314.
24. Citrome L. Patient perspectives in the development and use of long-acting antipsychotics in schizophrenia: focus on olanzapine long-acting injection. Patient Prefer Adherence 2009, 3:345-355.
25. McDonnell D.P., Detke H., Bergstrom R.F., et al. Post-injection delirium/sedation syndrome in patients with schizophrenia treated with olanzapine long-acting injection, II: investigations of mechanism. BMC Psychiatry 2010, 10:45.
26. Zyprexa RELPREVV [package insert]. Indianapolis, Ind: Eli Lilly and Company; 2011.